• Graph Blockchain (GBLC) is deploying subsidiary Optimum Coin Analyser’s Bitcoin trading software
  • Optimum Coin is an AI-driven analytics tool designed to predict the price of Bitcoin using social media data
  • Graph Blockchain provides shareholders with exposure to various areas of decentralized finance
  • Graph Blockchain (GBLC) opened trading at $0.055 per share

Graph Blockchain (GBLC) subsidiary, Optimum Coin Analyser has completed development of its trading software.

Optimum Coin is an AI-driven analytics tool designed to predict the price of Bitcoin. Optimum Coin continuously retrieves, observes, and analyses social media data using its AI SaaS coin trading research analytics engine to track influencers, monitor and provide sentiment relevance and predictive analysis while providing technical analysis.

The company will deploy the software with an initial investment of $100,000.

Paul Haber, Chief Executive Officer and Chairman of Graph Blockchain, commented on the news.

“The company is thrilled to have completed the development of Optimum Coin’s trading software. This has been a long-awaited project of ours, and we are excited to be one step closer to launching. We will continue hypothetical trading testing and deploy the software for customers very soon. We believe this software will make an impact in the Bitcoin industry, and we look forward to sharing more soon.” 

Graph Blockchain provides shareholders with exposure to various areas of decentralized finance, including altcoins and NFTs.

Graph Blockchain (GBLC) opened trading at $0.055 per share.


More From The Market Online

Pizza Pizza reports 12th straight quarter of sales growth in Q1 2024

Pizza Pizza (TSX:PZA) serves up good news for investors as it reports growth among its businesses in its Q1 2024 financial results.

Sterling Metals completes Copper Road Project acquisition

Sterling Metals (TSXV:SAG) completes the acquisition of the Copper Road Project in Ontario from Copper Road Resources (TSXV:CRD).
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.